This blinded, placebo-controlled Phase 1 study is designed to find out how much eloralintide slows stomach emptying in people with obesity or overweight. Its primary outcomes are acetaminophen absorption measures, which the registry title ties to delay in gastric emptying. Each participant is in the study about 21 weeks. Sites are in the United States and Singapore.
Read with care: it is a clinical-pharmacology study, not a weight-loss study. A registry record describes a study’s plan and status. It is not a result, and it does not show that the drug works or is safe.
Study context
What the study tests
This Phase 1 study asks how much eloralintide slows stomach emptying. The record measures this through acetaminophen (paracetamol) absorption: the primary endpoints are the acetaminophen AUC, peak concentration and time to peak. Investigators and participants are blinded, and multiple doses of eloralintide are compared with placebo. The record lists 56 participants, and each is in the study for about 21 weeks, including two overnight stays.
Who can take part
Adults aged 18 to 65 need a BMI from 27 to 45, a stable body weight and no diabetes, and must otherwise be healthy. The record excludes use of GLP-1 based drugs within 60 days or five half-lives before screening. Sites are in San Antonio, Texas and in Singapore.
What the registry does not say
No results are posted, so the record reports no measured delay in stomach emptying and does not say how large a delay would count as significant. Eloralintide drug levels are secondary measures. Primary completion is registered for December 2026.
Source: ClinicalTrials.gov record NCT07738614, read on 2026-10-15. Registered plans can change.